nCounter® Neuropathology Panel
Helping Your Research
Biomarker discovery and signature development are essential for identification of novel therapies and for earlier detection and development of therapies for neurodegenerative disorders like Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Amyotrophic Lateral Sclerosis (ALS). The nCounter Neuropathology Panel helps perform comprehensive multiplex gene expression analysis in human or mouse samples with genes involved in six fundamental themes of neurodegeneration: neurotransmission, neuron-glia interaction, neuroplasticity, cell structure integrity, neuroinflammation, and metabolism.
- Developed for research of Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Huntington’s Disease, and other neurological disorders
- Includes unique cell typing feature for measuring the abundance of five important CNS cell types, including neurons, astrocytes, microglia, oligodendrocytes, and endothelial cells
How It Works
nCounter Neuropathology Panels utilize NanoString’s unique barcoding technology and the nCounter Analysis System to help accelerate your research.
Screen 770 genes specific for neurodegeneration
Comprehensively Assess 23 pathways
Monitor progression of neurodegeneration
Screen potential therapeutics
Discover biomarkers and develop signatures associated with neurodegeneration
Customize with up to 55 additional user-defined genes with the Panel Plus option
Get data quickly with a streamlined, user-friendly, and efficient workflow with only 15 minutes hands-on time
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
Genes included in the Neuropathology Panels provide unique cell profiling data for measuring the abundance1 of five important cell types including neurons, astrocytes, microglia, oligodendrocytes, and endothelial cells. The table below summarizes each cell type represented in the panels along with the gene content qualified through current literature references.
1Danaher P. et al. Gene expression markers of Tumor Infiltrating Leukocytes JITC 2017
Functional annotations for 23 fundamental pathways and processes were assigned across all genes in the Neuropathology Panels allowing for a practical view of important aspects of the onset and progression of neurodegenerative disease.
Targeted Transcriptomic Analysis of C57BL/6 and BALB/c Mice During Progressive Chronic Toxoplasma gondii Infection Reveals Changes in Host and Parasite Gene Expression Relating to Neuropathology and Resolution.
Toxoplasma gondii is a resilient parasite that infects a multitude of warm-blooded hosts and results in a lifelong chronic infection requiring continuous responses by the host. Chronic infection is characterized by a balanced immune response and neuropathology that are driven by changes in gene expression.
A research parasite’s perspective on establishing a baseline to avoid errors in secondary analyses.
To enhance reproducibility in scientific research, more and more datasets are becoming publicly available so that researchers can perform secondary analyses to investigate questions the original scientists had not posited. This increases the return on investment for the NIH and other funding bodies.
Reduced erythrocytic CHCHD2 mRNA is associated with brain pathology of Parkinson’s disease.
Peripheral biomarkers indicative of brain pathology are critically needed for early detection of Parkinson’s disease (PD). In this study, using NanoString and digital PCR technologies, we began by screening for alterations in genes associated with PD or atypical Parkinsonism in erythrocytes of PD patients, in which PD-related changes have been reported, and which contain ~ 99% of blood α-synuclein.